enVVeno Medical (NVNO) Price & Analysis

Compare

361 Followers

NVNO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.76 - $5.70

Previous CloseN/A

Volume33.14K

Average Volume (3M)1.43M

Market Cap

$15.18M

Enterprise Value$46.94M

Total Cash (Recent Filing)$35.14M

Total Debt (Recent Filing)$882.00K

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Nov 06, 2025

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding19,247,140

10 Day Avg. Volume3,955,884

30 Day Avg. Volume1,426,936

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap3.09

Enterprise Value/Revenue57.81

Enterprise Value/Gross Profit1.88K

Enterprise Value/Ebitda-1.95

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

enVVeno Medical News

Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?

EnVVeno Medical stock fell hard on Wednesday after the company received a non-approval letter from the FDA. ...

16d ago

NVNO

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, economic data, deals, and more lead the biggest stock market stories for Wednesday! ...

17d ago

CRM

IBM

enVVeno Medical receives not-approvable letter from the FDA for VenoValve

enVVeno Medical (NVNO) received a not-approvable letter from the U.S. Food & Drug Administration in response to its...

17d ago

NVNO

enVVeno Medical Receives FDA Setback for VenoValve

enVVeno Medical ( ($NVNO) ) has shared an announcement. On August 20, 2025, enVVeno Medical Corporation announced it...

17d ago

NVNO

enVVeno participates in ‘What This Means’ segment on Trump’s CVI diagnosis

enVVeno Medical (NVNO) participated in a Virtual Investor “What This Means” segment entitled, “enVVeno Medical – Making Veins...

1M ago

NVNO

enVVeno Medical reports Q2 EPS (33c) vs. (31c) last year

“As the recent headlines around CVI confirmed, CVI is a pervasive and a progressive disease that is especially...

1M ago

NVNO

enVVeno Medical expects capital to fund company through 3Q26

The Company ended the quarter with $35.1 million in cash and investments. Based on management’s current expectations, this...

1M ago

NVNO

enVVeno Medical announces interim two-year follow-up data on VenoValve trial

enVVeno Medical (NVNO) announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S....

3M ago

NVNO

enVVeno Medical announces two-year data from VenoValve pivotal study

enVVeno Medical (NVNO) announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S....

3M ago

NVNO

enVVeno Medical Appoints New Chief Financial Officer

An update from enVVeno Medical ( ($NVNO) ) is now available. On May 19, 2025, enVVeno Medical Corporation...

4M ago

NVNO

enVVeno Medical appoints Jennifer Bright as CFO

enVVeno Medical (NVNO) announced the appointment of Jennifer Bright as CFO. Bright brings more than 25 years of...

4M ago

NVNO

enVVeno Medical appoints Jennifer Bright as CFO

enVVeno Medical (NVNO) announced the appointment of Jennifer Bright as CFO, effective May 19. Bright brings more than...

4M ago

NVNO

enVVeno Medical publishes three-year VenoValve data

enVVeno Medical (NVNO) announced that its manuscript titled, “Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve...

4M ago

NVNO

enVVeno Medical announces publication of VenoValve first-in-human trial data

enVVeno Medical (NVNO) announced that its manuscript titled, “Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve...

4M ago

NVNO

NVNO FAQ

What was Envveno Medical Corporation’s price range in the past 12 months?

Envveno Medical Corporation lowest stock price was $0.76 and its highest was $5.70 in the past 12 months.

What is Envveno Medical Corporation’s market cap?

Envveno Medical Corporation’s market cap is $15.18M.

When is Envveno Medical Corporation’s upcoming earnings report date?

Envveno Medical Corporation’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.

How were Envveno Medical Corporation’s earnings last quarter?

Envveno Medical Corporation released its earnings results on Aug 01, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.05.

Is Envveno Medical Corporation overvalued?

According to Wall Street analysts Envveno Medical Corporation’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Envveno Medical Corporation pay dividends?

Envveno Medical Corporation does not currently pay dividends.

What is Envveno Medical Corporation’s EPS estimate?

Envveno Medical Corporation’s EPS estimate is -0.3.

How many shares outstanding does Envveno Medical Corporation have?

Envveno Medical Corporation has 19,247,140 shares outstanding.

What happened to Envveno Medical Corporation’s price movement after its last earnings report?

Envveno Medical Corporation reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went up 5.64%.

Which hedge fund is a major shareholder of Envveno Medical Corporation?

Currently, no hedge funds are holding shares in NVNO

enVVeno Medical Stock Smart Score

Underperform

Fundamentals

Return on Equity

-64.55%

Trailing 12-Months

Asset Growth

-10.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Envveno Medical Corporation

enVVeno Medical Corporation (NVNO) is a healthcare company specializing in the development of innovative medical devices aimed at addressing venous diseases. The company's primary focus is on creating solutions for venous valve disorders, with products designed to improve the quality of life for patients suffering from chronic venous insufficiency (CVI). enVVeno Medical operates in the medical device sector, leveraging advanced research and technology to deliver effective treatment options.

enVVeno Medical (NVNO) Earnings & Revenues

Historic Earnings Reports

NVNO Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2019","6":"Sep<br/>2020","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.87,4.495384615384616,4.1207692307692305,3.746153846153846,3.371538461538462,2.996923076923077,2.6223076923076922,2.247692307692308,1.873076923076923,1.4984615384615383,1.123846153846154,0.7492307692307696,0.37461538461538435,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.51,"date":1564617600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.51,"date":1564617600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1569888000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1572566400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1577836800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1588291200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1598918400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >